Antibacterial Spectrum
|
|
- Herbert Hicks
- 5 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1992, p /92/ $02.00/0 Copyright 1992, American Society for Microbiology Vol. 36, No. 9 In Vitro and In Vivo Antibacterial Activities of, a Novel Parenteral Cephalosporin with a Broad Antibacterial Spectrum KATSURA HATA,* MASAKO OTSUKI, AND TAKESHI NISHINO Department of Microbiology, Kyoto Pharnaceutical University, 5-Nakauchi-cho, Misasagi, Yamashina-ku, Kyoto 607, Japan Received 3 February 1992/Accepted 3 July 1992 is a new iijectable cephalosporin with a broad spectrum of antibacterial activity against gram-positive and gram-negative bacteria, including staphylococci and Pseudomonas aeruginosa. The in vitro activities of against clinical isolates of methicillin-susceptible Staphylococcus aureus (MIC of for 90%o of the strains tested [MIC,0], ;g/ml) and methicillin-resistant S. aureus (MIC90, plg/ml) were similar to those of cefpirome and flomoxef. Against Enterococcusfaecalis (MIC,0, 6. ;ag/ml), was the most active of the drugs tested and four times more active than cefpirome. The MIC90s of for streptococci, Haemophilus influenzae, and Neisseria gonorrhoeae ranged from to,ug/ml; was similar in activity to cefpirome. inhibited 90% of most species of the family Enterobacteriaceae at concentrations of < ilg/ml, with the exception of Serratia marcescens and Proteus vulgaris (,ug/ml). The activity of against P. aeruginosa (MIC90, 6. ;Lg/ml) was comparable to that of ceftazidime. In vivo activity was evaluated with systemic infections in mice. showed a protective effect against systemic infections by gram-positive or gram-negative bacteria, as reflected by its in vitro activity. The protective effects of were higher than those of cefpirome against S. aureus and P. aeruginosa infections and similar to those of cefpirome against other bacterial infections. Morphological studies using differential interference and phase-contrast microscopy showed that low concentrations of caused swelling of S. aureus and spheroplast and bulge formation in P. aeruginosa. In general, the antibacterial profile of is similar to that of cefpirome. The newer cephalosporin antibiotics used in the treatment of bacterial infections, such as ceftazidime, cefuzonam, and flomoxef, possess broad antibacterial spectra. However, infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa still cause major clinical problems. Accordingly, there has been continued interest in producing cephalosporins with increased activity against MRSA or P. aeruginosa, such as cefpirome (12), cefepime (5), and E1040 (14). {7,B-[2-(5-amino- 1,2,4-thiadiazol-3-yl)-(Z)-2-fluoromethoxyiminoacetamido]- 3 - [(E) (carbamoylmethyl) ethylmethylammonio propenyl] cephem carboxylate} is a new parenteral cephalosporin synthesized by Eisai Co., Ltd., Tokyo, Japan. It contains a unique side chain, a propenylammonium moiety at the 3 position, and a monofluoromethoxyimino group in the 71 side chain of the cephalosporin nucleus and has a broad antibacterial spectrum (4). In this study, we compared the in vitro and in vivo antibacterial activities of with those of cefpirome (12), ceftazidime (15), cefuzonam (2), cefotaxime (9), and flomoxef (8) and examined the morphological changes in S. aureus and P. aeruginosa induced by. MATERIALS AND METHODS Antibiotics. was provided by Eisai Co., Ltd. was provided by Hoechst Japan, Tokyo, Japan. The following other antibiotics were obtained commercially: ceftazidime (Tanabe Pharmaceutical Co., Osaka, Japan), * Corresponding author cefuzonam (Takeda Chemical Industries, Osaka, Japan), cefotaxime (Chugai Pharmaceutical Co., Tokyo, Japan), and flomoxef (Shionogi Pharmaceutical Co., Osaka, Japan). Organisms. The bacterial strains used in this study were distinct clinical isolates obtained from various hospitals in Japan between 1985 and All isolates were maintained as stock cultures in our laboratory. Determination of MICs. MICs were determined by the agar dilution method recommended by the Japan Society of Chemotherapy (1). Sensitivity test agar (Eiken) was used for all organisms except the following: streptococci (sensitivity test agar supplemented with 10% defibrinated horse blood), Haemophilus influenzae (sensitivity test agar supplemented with 5% Fildes enrichment), Branhamella catarrhalis (chocolate sensitivity test agar supplemented with 5% defibrinated horse blood), and Neisseria gonorrhoeae (chocolate sensitivity test agar supplemented with 10% defibrinated horse blood). Fresh cultures of the bacterial strains were diluted, and 5 pl of each bacterial suspension, corresponding to about 104 CFU, was spotted (Microplanter; Sakuma Seisakusho, Tokyo, Japan) onto agar plates that contained twofold serial dilutions of antibiotics. The MIC was the lowest concentration of an antibiotic that completely inhibited visible growth on agar plates after incubation for 18 h at 37 C. For N. gonorrhoeae, incubation was carried out in a candle jar. The MIC and MIC90 were the concentrations of a drug required to inhibit % and 90% of the strains, respectively. Differential interference and phase-contrast microscopy. S. aureus Smith and P. aeruginosa E-2 were incubated in sensitivity test broth for 3 h at 37 C and then incubated on sensitivity test agar plates containing different concentra-
2 VOL. 36, 1992 IN VITRO AND IN VIVO ACTIVITIES OF 1895 TABLE 1. Antibacterial activities of and reference compounds against clinical isolates Organism Antibacterial MIC (ILg/ml) (no. of strains) agent Range % 90% Methicillin-susceptible Staphylococcus aureus (91) MRSA (132) Staphylococcus epidermidis (67) Streptococcus pneumoniae (33) Streptococcus pyogenes (52) Enterococcus faecalis (40) Neisseria gonorrhoeae (31) Haemophilus influenzae (52) Branhamella catarrhalis (52) > -> - - -> -> -> - < < ! : , < < f : Continued on following page
3 1896 HATA ET AL. ANTIMICROB. AGENTS CHEMOTHER. Escherichia coli (40) Kiebsiella pneumoniae (40) Enterobacter cloacae (39) TABLE 1-Continued Organism Antibacterial MIC (,Lg/ml) (no. of strains) agent Range % 90% Enterobacter aerogenes (39) Citrobacterfreundii (34) Serratia marcescens (39) Proteus mirabilis (38) Proteus vulgaris (40) Morganella morganii (40) ' Continued on following page
4 VOL. 36, 1992 IN VITRO AND IN VIVO ACTIVITIES OF 1897 TABLE 1-Continued Organism Antibacterial MIC (,ug/ml) (no. of strains) agent Range % 90% Providencia rettgeri (36) ' Pseudomonas aeruginosa () > -> > -> > > Acinetobacter calcoaceticus (32) tions of. After 3 h of incubation, morphological changes of cells were examined by differential interference microscopy for S. aureus and by phase-contrast microscopy for P. aeruginosa. Systemic infection in mice. The protective effect of against systemic infections in mice was determined as described previously (3). Male ddy strain mice weighing 18 to 20 g were used. The bacterial strains, except for Streptococcuspneumoniae type III, were cultured overnight at 37 C in nutrient broth (Nissui). For S. pneumoniae, broth was supplemented with 10% horse serum. Challenge organisms were prepared in nutrient broth and 3% hog mucin (Orthana Kemisk Fabrik A/S) in sterile water. The mice were injected intraperitoneally with 0.5 ml of the bacterial suspension. The challenge inoculum was sufficient to kill % of untreated control mice within 48 h postinfection, with the exception of Downloaded from on November 14, 2018 by guest FIG. 1. Differential interference micrographs of S. aureus Smith exposed to for 3 h. Panels: A, untreated control; B,,ug/ml; C, 0.1 plg/ml; D, pg/ml; E,.g/ml; F, 6.,g/ml.
5 1898 HATA ET AL. ANTIMICROB. AGENTS CHEMOTHER. FIG. 2. Phase-contrast micrographs of P. aeruginosa E-2 exposed to for 3 h. Panels: A, untreated control; B, 1Lg/ml; C,,ug/ml; D, 6.,ug/ml; E,,ug/ml; F,,ug/ml. mice infected with Klebsiella pneumoniae KC-1 or P. aeruginosa 15846, which died within 3 days after challenge. The antibiotic doses were administered subcutaneously in a volume of 0.2 ml of normal saline 2 h after infection. At least five levels (serial twofold doses) of the test compounds were employed with 10 mice at each level, and the 7-day survival ratios were determined. The % effective dose (ED) was calculated by the Litchfield-Wilcoxon method (7). RESULTS Antibacterial activity. The antibacterial activities of, cefpirome, ceftazidime, cefuzonam, flomoxef, and cefotaxime against clinical isolates are shown in Table 1. was active against staphylococci. The MIC90 of for methicillin-susceptible S. aureus strains was,ug/ml, which was similar to those of cefpirome, cefuzonam, and flomoxef and 1/16 to 1/4 times those of cefotaxime and ceftazidime. The MIC and MIC90 of for MRSA strains were 6. and,ug/ml, respectively. Its MIC was similar to that of flomoxef and eight times lower than those of cefuzonam and cefpirome, and its MIC-w was similar to those of cefpirome, cefuzonam, and flomoxef. and cefotaxime were inactive against MRSA, with MICs of,ug/ml. The activity of was comparable to that of cefpirome and cefuzonam against Staphylococcus epidermidis. Against streptococci, was comparable to cefpirome and cefotaxime and 4 to 16 times more active than ceftazidime and flomoxef. However, was four times less active than cefuzonam against S. pneumoniae., with an MIC90 of 6.,ug/ml for Enterococcus faecalis, was the most potent of the compounds tested. It was four times more active than cefpirome. The other reference compounds did not inhibit most strains of E. faecalis at a concentration of,ug/ml or less. The MIC90s of for N. gonorrhoeae and H. influenzae were and,ug/ml, respectively. was 4 to 16 times more active against these species than was flomoxef and was comparable to the other compounds tested. Against B. catarrhalis,, with an MIC90 of,ug/ml, was four times more active than cefpirome but eight times less active than ceftazidime. In general, and cefpirome were more active against most members of the family Enterobacteriaceae than were the other compounds tested. The MIC90s of for Escherichia coli and K pneumoniae were and,ug/ml, respectively. was equal to or four times more active than cefpirome against these species. The MIC90s of for Enterobacter cloacae, Enterobacter aerogenes, and Citrobacter freundii were,, and jig/ml, respectively, and was equal to or four times more active than cefpirome and 64 to > 128 times more active than ceftazidime, cefuzonam, cefotaxime, and flomoxef against these species. Against Serratia marcescens, was comparable to cefpirome and eight or more times more active than the other reference compounds, with an MIC90 of,ug/ml. Against Morganella morganii and Providencia rettgeri, was equal to or 4 times more active than cefpirome and 4 to 64 times more active than ceftazidime and cefuzonam, with MIC90s of and,g/ml, respectively. was similar in activity to cefpirome, ceftazidime, and cefotaxime and four times more active than cefuzonam against Proteus mirabilis. was four or more times less active than these reference compounds against Proteus vulgaris.
6 VOL. 36, 1992 IN VITRO AND IN VIVO ACTIVITIES OF 1899 Organism TABLE 2. Staphylococcus aureus Smith Streptococcus pneumoniae type III Escherichia coli KC-14 Klebsiella pneumoniae KC-1 Citrobacterffreundii B3 Serratia marcescens T-55 Pseudomonas aeruginosa Acinetobacter calcoaceticus Ac-54 a LD, % lethal dose. Protective effects of and reference compounds against systemic infection in mice Challenge dose, CFU/mouse (no. of LDSa) 3.3 x 106 (260) 6.6 x 10 (90) 1.5 x 105 (90) 2.4 x 104 (26) 1.7 x 106 (22) 2.1 x 106 (80) 7.5 x 104 (74) 2.2 x 105 (18) Against P. aeruginosa, the activity of was similar to that of ceftazidime. The MIC and MIC90 of for P. aeruginosa were and 6.,ug/ml, respectively. The MIC of was equal to or four times lower than those of ceftazidime and cefpirome. was as active as cefpirome and ceftazidime against Acinetobacter calcoaceticus, with an MIC of,ug/ml and an MIC90 of p,g/ml. Morphological effects. The morphological changes induced by in S. aureus Smith and P. aeruginosa E-2 were examined by differential interference and phase-contrast microscopy, respectively. In S. aureus (Fig. 1), induced a little swelling at a concentration of one-fourth of the MIC and lysis above the MIC. In P. aeruginosa (Fig. 2), induced formation of filamentatous cells from nor- Test compound MIC (F±g/ml) ED, mg/kg (95% confidence limits) ( ) ( ) 9.17 ( ) 3.07 ( ) ( ) 2.18 ( ) 4.19 ( ) 37.0 ( ) 12.7 ( ) 2.78 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 12.3 ( ) ( ) ( ) ( ) 16.3 ( ) ( ) ( ) 7 ( ) ( ) 3.35 ( ) 2.66 ( ) 11.7 ( ) 5.70 ( ) >200 > ( ) 9.31 ( ) 8.90 ( ) 97.1 ( ) ( ) mally rod-shaped cells at concentrations of one-fourth to four times the MIC. When P. aeruginosa cells were exposed to high concentrations of ( and,ug/ml), formation of spheroplasts and bulges and cell lysis were observed. Activity against systemic infections in mice. The in vivo activity of against systemic infections in mice is shown in Table 2. showed in vivo activity against gram-positive and gram-negative bacterial infections, as reflected by its in vitro activity. The ED of against S. aureus was mg/kg; was comparable to flomoxef, 3 times more effective than cefpirome, and 10 to 30 times more effective than cefuzonam and ceftazidime. Against S. pneumoniae infection, the activity of was comparable to those of cefpirome and flomoxef and about 5
7 1900 HATA ET AL. to 17 times those of ceftazidime and cefuzonam. The activities of against E. coli and K pneumoniae infections, with EDs of and mg/kg, respectively, were similar to those of cefpirome and higher than those of the other reference compounds. The ED of against C. freundii was mg/kg; was similar in efficacy to cefpirome and 10 to 20 times as effective as the other reference compounds. Against S. marcescens infection, the activity of (ED, mg/kg) was comparable to those of cefpirome and ceftazidime and about 5 to 20 times those of cefuzonam and flomoxef. was also effective against P. aeruginosa infection. The activity of, with an ED of 2.66 mg/kg, was similar to that of ceftazidime and four times that of cefpirome, while cefuzonam and flomoxef were ineffective against P. aeruginosa infection. Against A. calcoaceticus infection, the activity of (ED, 4.88 mg/kg) was comparable to those of cefpirome and ceftazidime and about 20 times higher than those of cefuzonam and flomoxef. DISCUSSION is a new injectable cephalosporin, which has been described by Watanabe et al. (13), with a broad antibacterial spectrum and potent antibacterial activity. One of the antibacterial characteristics of is its activity against S. aureus and E. faecalis. The activity of against methicillin-susceptible S. aureus was comparable to those of cefpirome, cefuzonam, and flomoxef. also inhibited % and 90% of MRSA strains at concentrations of 6. and,ug/ml, respectively. Its activity was similar to that of flomoxef, which has been reported to be more active in vitro than other cephalosporins against MRSA (8). However, its activity, with an MIC90 of,ug/ml, is probably inadequate for clinical use for MRSA infections. In addition, was active against E. faecalis, which was resistant or less susceptible to most of the existing cephalosporins. The MIC90 of for E. faecalis was 6.,ug/ml, and its activity was four times that of cefpirome. The other reference compounds were inactive (MICs,,ug/ml). Kamiya et al. have suggested that the high activity of against S. aureus and E. faecalis is provided by the introduction of a quatemary ammoniopropenyl substituent at the 3 position of the cephem nucleus (4). A second characteristic of is that is very effective against most members of the family Enterobacteriaceae. In general, the activity of was comparable to that of cefpirome and higher than those of the other reference compounds against these species. In particular, the activity of was much higher (.64 times) than those of ceftazidime, cefuzonam, cefotaxime, and flomoxef against Enterobacter and Citrobacter species, which produce high levels of chromosomal,-lactamase (11). (6) and cefepime (10) have been reported to be active against these species. In this study, was four times more active than cefpirome against E. aerogenes and C. freundii. also showed higher in vivo activity against systemic infection caused by a strain of C. freundii that was resistant to the other extended-spectrum cephalosporins than did ceftazidime and cefuzonam. This activity seems to be due to the resistance of to enzymatic hydrolysis and the low affinity of the compound for 1-lactamases (13). possessed potency comparable to that of ceftazidime against P. aeruginosa, an opportunistic pathogen that is one of the major causes of life-threatening nosocomial ANTIMICROB. AGENTS CHEMOTHER. bacterial infections. The M'C and MIC90 of for P. aeruginosa were and 6.,ug/ml, respectively, and its activity was comparable to that of ceftazidime and four times higher than that of cefpirome. Watanabe et al. have reported that introduction of the aminothiadiazolyl group in the 71 side chain of the cephem nucleus enhances antibacterial activity against P. aeruginosa (14). The in vivo activity of in systemic infection clearly reflected its in vitro activity against P. aeruginosa. Thus, has a broad antibacterial spectrum covering gram-positive bacteria, including staphylococci and E. faecalis, and gram-negative bacteria, including P. aeruginosa. The in vitro study results were generally consistent with those of Watanabe et al. (13). also showed efficacy in systemic infections with various bacteria, and this was clearly reflected by its in vitro activity. Overall, is a very promising antibacterial agent for the treatment of various bacterial infections. Further studies on pharmacokinetic and toxicological behaviors are therefore warranted. ACKNOWLEDGMENT This study was financially assisted by Eisai Co., Ltd. REFERENCES 1. Committee for Revision of MIC Determination Method Revision of minimal inhibitory concentration (MIC) determination method. Chemotherapy (Tokyo) 29: Hikida, M., M. Inoue, and S. Mitsuhashi In vitro antibacterial activity of L-105, a new cephalosporin. J. Antimicrob. Chemother. 18: Hiruma, R., M. Otsuki, M. Tashima, Y. Obana, and T. Nishino In-vitro and in-vivo antibacterial activities of E1040, a new cephalosporin with potent antipseudomonal activity. J. Antimicrob. Chemother. 26: Kamiya, T., T. Naito, Y. Kai, Y. Komatsu, M. Sasho, N. Sato, T. Nakamura, S. Negi, Y. Machida, and Y. Yamauchi Program Abstr. 30th Intersci. Conf. Antimicrob. Agents Chemother., abstr Kessler, R. E., M. Bies, R. E. Buck, D. R. Chisholm, T. A. Pursiano, Y. H. Tsai, M. Misiek, K. E. Price, and F. Leitner Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum,3-lactam antibiotics. Antimicrob. Agents Chemother. 27: Kobayashi, S., S. Arai, S. Hayashi, and K. Fujimoto P-Lactamase stability of cefpirome (HR810), a new cephalosporin with a broad antibacterial spectrum. Antimicrob. Agents Chemother. 30: Litchfield, J. T., Jr., and F. Wilcoxon A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96: Murakami, K., K. Nomura, M. Doi, and T. Yoshida Production of low-affinity penicillin-binding protein by low- and high-resistance groups of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 31: Neu, H. C., N. Aswapokee, P. Aswapokee, and K. P. Fu HR756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 15: Phelps, D. J., D. D. Carlton, C. A. Farrell, and R. E. Kessler Affinity of cephalosporins for P-lactamases as a factor in antibacterial efficacy. Antimicrob. Agents Chemother. 29: Sanders, C. C Chromosomal cephalosporinases responsible for multiple resistance to newer 3-lactam antibiotics. Annu. Rev. Microbiol. 41: Seibert, G., M. Limbert, I. Winkler, and T. Dick Antibacterial activity in vitro and P-lactamase stability of the new
8 VOL. 36, 1992 cephalosporin HR810 in comparison with five other cephalosporins and two aminoglycosides. Infection 11: Watanabe, N., R. Hiruma, and K. Katsu In vitro evaluation of, a new cephalosporin with a broad antibacterial spectrum. Antimicrob. Agents Chemother. 36: Watanabe, N., K. Katsu, M. Moryama, and K. Kitoh In IN VITRO AND IN VIVO ACTIVITIES OF 1901 vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity. Antimicrob. Agents Chemother. 32: Wise, R., J. H. Andrews, and K. A. Bedford Comparison of in vitro activity of GR20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Antimicrob. Agents Chemother. 17:
In Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone
More information4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases
4 th and 5 th generation cephalosporins Naderi HR Associate professor of Infectious Diseases Classification Forth generation: Cefclidine, cefepime (Maxipime),cefluprenam, cefoselis,cefozopran, cefpirome
More informationIn Vitro and In Vivo Antibacterial Activities of T-3761, a New Quinolone Derivative
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1993, p. 384-392 0066-4804/93/030384-09$02.00/0 Copyright 1993, American Society for Microbiology Vol. 37, No. 3 In Vitro and In Vivo Antibacterial Activities
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationwith Stability to Dehydropeptidase I
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 99, p. 5- Vol. 33, No. 0066-0/9/005-0$0.00/0 Copyright C 99, American Society for Microbiology In Vitro Antibacterial Activity of, a Carbapenem Antibiotic with
More informationSpectrum Cephalosporin with Antipseudomonal Activity
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1983, p. 195-200 Vol. 23, No. 2 00664804/83/020195S06$02.00/0 Copyright C 1983, American Society for Microbiology In Vitro Antibacterial Activity of, a New Broad-
More informationIn Vitro Activity of DR-3355, an Optically Active Ofloxacin
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1988, p. 1336-1340 0066-4804/88/091336-05$02.00/0 Copyright C 1988, American Society for Microbiology Vol. 32, No. 9 In Vitro Activity of, an Optically Active
More informationC&W Three-Year Cumulative Antibiogram January 2013 December 2015
C&W Three-Year Cumulative Antibiogram January 213 December 215 Division of Microbiology, Virology & Infection Control Department of Pathology & Laboratory Medicine Contents Comments and Limitations...
More informationIn Vitro Activity of Netilmicin, Gentamicin, and Amikacin
ANTIMICROBIAL AGzNTS AND CHEMOTHERAPY, Jan. 1977, p. 126-131 Copyright X 1977 American Society for Microbiology Vol. 11, No. 1 Printed in U.S.A. In Vitro Activity of Netilmicin, Gentamicin, and Amikacin
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationAberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015
Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More information2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)
Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according
More informationBacteriological Characterization
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1978, p. 414-419 0066-4804/78/0014-0414$02.00/O Copyright X) 1978 American Society for Microbiology Vol. 14, No. 3 Printed in U.S.A. CP-45,899, a Beta-Lactamase
More informationGuidelines for Laboratory Verification of Performance of the FilmArray BCID System
Guidelines for Laboratory Verification of Performance of the FilmArray BCID System Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes quality standards for all laboratory
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationAntimicrobial susceptibility
Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL
More informationIn Vitro Activity of S-3578, a New Broad-Spectrum Cephalosporin Active against Methicillin-Resistant Staphylococci
REFERENCES CONTENT ALERTS In Vitro Activity of S-3578, a New Broad-Spectrum Cephalosporin Active against Methicillin-Resistant Staphylococci Takaji Fujimura, Yoshinori Yamano, Isamu Yoshida, Jingoro Shimada
More informationTable 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationTOLYPOMYCIN, A NEW ANTIBIOTIC. V IN VITRO AND IN VIVO ANTIMICROBIAL ACTIVITY. Masahiro Kondo, Tokiko Oishi and Kanji Tsuchiya
16 THE JOURNAL OF ANTIBIOTICS JAN. 1972 TOLYPOMYCIN, A NEW ANTIBIOTIC. V IN VITRO AND IN VIVO ANTIMICROBIAL ACTIVITY Masahiro Kondo, Tokiko Oishi and Kanji Tsuchiya Biological Research Laboratories, Research
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationEvaluation of the BIOGRAM Antimicrobial Susceptibility Test System
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 1985, p. 793-798 0095-1137/85/110793-06$02.00/0 Copyright 1985, American Society for Microbiology Vol. 22, No. 5 Evaluation of the BIOGRAM Antimicrobial Susceptibility
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationIn Vitro Activity of Piperacillin, a New Semisynthetic Penicillin with an Unusually Broad Spectrum of Activity
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, March 1978, p. 349-357 66-484/8/133-349$2./ Copyright 1978 American Society for Microbiology Vol. 13, No. 3 Printed in U.S.A. In Vitro Activity of Piperacillin, a
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More information2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital
2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....
More information2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital
2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationEvaluation of the AutoMicrobic System for Susceptibility Testing of Aminoglycosides and Gram-Negative Bacilli
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 1987, p. 546-550 0095-1137/87/030546-05$02.00/0 Copyright C 1987, American Society for Microbiology Vol. 25, No. 3 Evaluation of the AutoMicrobic System for Susceptibility
More informationDoripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities
REVIEW Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities Fiona Walsh Department of Clinical Microbiology, Trinity College Dublin, Dublin, Ireland
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More information6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS
6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS 6.1 INTRODUCTION Microorganisms that cause infectious disease are called pathogenic microbes. Although
More informationUniversity, New York, New York Received for publication 7 May was measured by the broth dilution method as previously
ANTmIcaoBIAL AGuNTS AND CHUMTrHURAPY, Sept. 1976, p. 526-534 Copyright C 1976 American Society for Microbiology Vol. 10, No. 3 Printed in U.S.A. In Vitro Study of Netilmicin Compared with Other Aminoglycosides
More informationQ1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants.
Q1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants. C. difficile rarely causes problems, either in healthy adults or in infants.
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationComparative Activity of Netilmicin, Gentamicin, Amikacin, and Tobramycin Against Pseudomonas aeruginosa and Enterobacteriaceae
ANTIMICROBIAL AGzNTS AND CHEMOTHERAPY, Oct. 1976, P. 592-597 Copyright 1976 American Society for Microbiology Vol. 1, No. 4 Printed in U.S.A. Comparative Activity of Netilmicin, Gentamicin, Amikacin, and
More informationRCH antibiotic susceptibility data
RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological
More informationINFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More information2015 Antimicrobial Susceptibility Report
Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf
More informationReassessment of the "Class" Concept of Disk Susceptibility Testing
Reassessment of the "Class" Concept of Disk Susceptibility Testing Disks versus Minimal Inhibitory Concentrations with Eleven Cephalosporins ARTHUR L. BARRY, PH.D., CLYDE THORNSBERRY, PH.D., RONALD N.
More informationMICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,
More informationLeveraging the Lab and Microbiology Department to Optimize Stewardship
Leveraging the Lab and Microbiology Department to Optimize Stewardship Presented by: Andrew Martinez MLS(ASCP), MT(AMT), MBA Alaska Native Medical Center Microbiology Supervisor Maniilaq Health Center
More informationIV Antibiotics for Lyme Disease (Ceftriaxone, Cefotaxime sodium, Doxycycline, Penicillin G potassium)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.15 Subject: IV Antibiotics Lyme Disease Page: 1 of 9 Last Review Date: November 30, 2018 IV Antibiotics
More informationCipro for gram positive cocci in urine
Buscar... Cipro for gram positive cocci in urine 20-6-2017 Pneumonia can be generally defined as an infection of the lung parenchyma, in which consolidation of the affected part and a filling of the alveolar
More informationWhat s next in the antibiotic pipeline?
What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics
More informationSYMMETRY FOAMING HAND SANITIZER with Aloe & Vitamin E Technical Data
508 SYMMETRY FOAMING HAND SANITIZER with Aloe & Vitamin E Technical Data Physical Properties Active Ingredient: Ethyl Alcohol 62% (70% v/v) Appearance: Clear, Colorless Solution Fragrance: Floral Form:
More informationIN VITRO COMBINATION EFFECTS OF NORFLOXACIN, GENTAMICIN, AND Ĉ- LACTAMS ON Ĉ- LACTAM RESISTANT PSEUDOMONAS AERUGINOSA
IN VITRO COMBINATION EFFECTS OF NORFLOXACIN, GENTAMICIN, AND Ĉ- LACTAMS ON Ĉ- LACTAM RESISTANT PSEUDOMONAS AERUGINOSA YONGYUTH JITTAROPAS NAOTO 1), RIKITOMI 2), and Kaizo MATSUMOTO 2) 1) Department of
More informationEXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING
EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationFig. 1. Bactericidal effect of guinea-pig complement against E. coil NIHJ JC-2, P. aeruginosa 18 S and S. aureus 209 P
Fig. 1. Bactericidal effect of guinea-pig complement against E. coil NIHJ JC-2, P. aeruginosa 18 S and S. aureus 209 P Table 1. IDsos of the test antibiotics against each strain of bacterium Fig. 2. Synergy
More informationSusceptibility Testing and Resistance Phenotypes Detection in Bacterial Pathogens Using the VITEK 2 System
Polish Journal of Microbiology 2005, Vol. 54, No 4, 311 316 Susceptibility Testing and Resistance Phenotypes Detection in Bacterial Pathogens Using the VITEK 2 System EL BIETA STEFANIUK*, AGNIESZKA MRÓWKA
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationCUMULATIVE ANTIBIOGRAM
BC Children s Hospital and BC Women s Hospital & Health Centre CUMULATIVE ANTIBIOGRAM 2017 Division of Medical Microbiology Department of Pathology and Laboratory Medicine Page 1 of 5 GRAM-POSITIVE BACTERIA
More informationVOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill
VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559 ANTIBIOTIC 6640.* Ill BIOLOGICAL STUDIES WITH ANTIBIOTIC 6640, A NEW BROAD-SPECTRUM AMINOGLYCOSIDE ANTIBIOTIC J. Allan Waitz, Eugene L. Moss, Jr., Edwin
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationStaphylococcus aureus
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, OCt. 1981, p. 463-469 0066-4804/81/100463-07$02.00/0 Vol. 20, No. 4 In Vitro and In Vivo Studies of Three Antibiotic Combinations Against Gram-Negative Bacteria and
More informationDisk Susceptibility Studies with Cefazolin and Cephalothin
ANTIMICROBiAL AGENTS AND CHEMOTHEMRAPY, Jan. 1974, p. 63-67 Copyright i 1974 American Society for Microbiology Vol. 5, No. 1 Printed in U.SA. Disk Susceptibility Studies with Cefazolin and Cephalothin
More informationChapter Anaerobic infections (individual fields): prevention and treatment of postoperative infections
J Infect Chemother (2011) 17 (Suppl 1):62 66 DOI 10.1007/s10156-010-0141-x GUIDELINES Chapter 2-5-1. Anaerobic infections (individual fields): prevention and treatment of postoperative infections Ó Japanese
More informationwith Other Orally Administered Drugs
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1983, p. 209-215 0066-4804/83/080209-07$00/0 Copyright C 1983, American Society for Microbiology Vol. 24, No. 2 In Vitro Evaluation of Three New Macrolide Antimicrobial
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationAminoglycoside-resistant enterococci
Aminoglycoside-resistant enterococci M. J. BASKER, B. SLOCOMBE, AND R. SUTHERLAND From Beecham Pharmaceuticals Research Division, Brockham Park, Betchworth, Surrey J. clin. Path., 1977, 30, 375-380 SUMMARY
More informationSelective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016
Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that
More informationF. Gouin% L. Papazian", C. Martin*, J. Albanese*, O. Durbec*, Y. Domarf, P. Veyssier% J. Leroy'', J. J. Gres' and C. Rollin'
Journal of Antimicrobial Chemotherapy (993) 32, Suppl. B, 25-24 A non-comparative study of the efficacy and tolerance of cefepime in combination with amikacin in the treatment of severe infections in patients
More informationETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens
ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens Ruben Tommasi, PhD Chief Scientific Officer ECCMID 2017 April 24, 2017 Vienna, Austria
More informationComparison of the Inhibitory and Bactericidal Activity of Aztreonam and Amikacin Against Gram Negative Aerobic Bacilli
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 18, No. 6 Copyright 1988, Institute for Clinical Science, Inc. Comparison of the Inhibitory and Bactericidal Activity of Aztreonam and Amikacin Against Gram
More informationETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
More informationActivity of Three Aminoglycosides and Two Penicillins Against
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1975, P. 172-178 Copyright @ 1975 American Society for Microbiology Vol. 7, No. 2 Printed in U.S.A. Activity of Three Aminoglycosides and Two Penicillins Against
More informationLiofilchem Chromatic Chromogenic culture media for microbial identification and for the screening of antimicrobial resistance mechanisms
Liofilchem Chromatic Chromogenic culture media for microbial identification and for the screening of antimicrobial resistance mechanisms Microbiology Products since 1983 Liofilchem Chromatic ESBL Selective
More informationLab Exercise: Antibiotics- Evaluation using Kirby Bauer method.
Lab Exercise: Antibiotics- Evaluation using Kirby Bauer method. OBJECTIVES 1. Compare the antimicrobial capabilities of different antibiotics. 2. Compare effectiveness of with different types of bacteria.
More informationC.D.S. USERS GROUP. NEWSLETTER No. 3. Report of the CDS Users Group Workshop held at the. ASM Gold Coast Meeting 1991
THE PRINCE OF WALES HOSPITAL The Prince of Wales Hospital, Cnr. High & Avoca Streets, Randwick. N.S.W. 2031. SMB/BG 20 th August, 1991. Dear Colleague, C.D.S. USERS GROUP NEWSLETTER No. 3 Report of the
More informationavailable. and P. aeruginosa resistant to gentamicin by standardized disk testing (1) in the Microbiology Laboratory
ANTimICROBIAL AGENTh AND CHEMOTHERAPY, OCt. 1976, p. 677-681 Copyright 1976 American Society for Microbiology Vol. 10, No. 4 Printed in U.S.A. In Vitro Susceptibility of Gentamicin-Resistant Enterobacteriaceae
More informationDefining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing
Infect Dis Ther (2015) 4:513 518 DOI 10.1007/s40121-015-0094-6 BRIEF REPORT Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate
More informationJAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro
Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry
More informationIn vitro Activity of Gemifloxacin Against Recent Clinical Isolates of Bacteria in Korea
J Korean Med Sci 2002; 17: 737-42 ISSN 1011-8934 Copyright The Korean Academy of Medical Sciences In vitro Activity of Gemifloxacin Against Recent Clinical Isolates of Bacteria in Korea Gemifloxacin is
More informationFundamental Concepts in the Use of Antibiotics. Case. Case. TM is a 24 year old male admitted to ICU after TBI and leg fracture from MVA ICU day 3
Fundamental Concepts in the Use of Antibiotics Todd Miano, PharmD, MSCE Critical Care Pharmacist Pharmacoepidemiology Fellow Perelman School of Medicine at the University of Pennsylvania Case TM is a 24
More informationUK Journal of Pharmaceutical and Biosciences Available at ISSN:
UK Journal of Pharmaceutical and Biosciences Vol. 5(2), 45-49, 2017 RESEARCH ARTICLE UK Journal of Pharmaceutical and Biosciences Available at www.ukjpb.com ISSN: 2347-9442 Anti-Microbial Susceptibility
More informationln-vitro activity of newer quinolones against aerobic bacteria
Journal of Antimicrobial Chemotherapy (96) 7, Suppl. B, 9-39 ln-vitro activity of newer quinolones against aerobic bacteria R. Anckenthaler, M. Michea-Hamzehponr and J. C. Pectere Laboratoire Central de
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
More informationIn Vivo Efficacy of the Novel Aminoglycoside ACHN-490 in Murine Infection Models
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2011, p. 1728 1733 Vol. 55, No. 4 0066-4804/11/$12.00 doi:10.1128/aac.00862-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. In Vivo
More informationOther β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
More informationCF WELL Pharmacology: Microbiology & Antibiotics
CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017 Disclosure
More informationmicrobiology testing services
microbiology testing services You already know Spectra Laboratories for a wide array of dialysis-related testing services. Now get to know us for your microbiology needs. As the leading provider of renal-specific
More informationIn Vitro Activities of the Novel Cephalosporin LB against Multidrug-Resistant Staphylococci and Streptococci
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2004, p. 53 62 Vol. 48, No. 1 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.1.53 62.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationAminothiazolyl oc-methoxyimino Cephalosporin
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 1984, p. 710-718 0066-4804/84/060710-09$00/0 Copyright 1984, American Society for Microbiology Vol. 25, No. 6 In Vitro Evaluation of, a New Wide-Spectrum Aminothiazolyl
More informationnumber Done by Corrected by Doctor Dr.Malik
number 27 Done by Fatimah Farhan Corrected by Basil Al-Bakri Doctor Dr.Malik Note: anything in red is just extra info and you will not be asked about it in the exam. In this sheet we will continue talking
More information